# US 2012/0269819 A1 · Human Anti-IFN-gamma Neutralizing Antibodies as Selective IFN-gamma Pathway Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269819 A1
- Document ID: US20120269819A1
- Status: Published application
- Kind: A1
- Application number: 13/476,317
- Filed: 2012-05-21
- Published: 2012-10-25
- Earliest claimed: 2002-10-16
- Assignees: Medarex, Inc.; Amgen Inc.
- Inventors: Andrew A. Welcher; Hilary T. Chute; Yue-Sheng Luke Li; Haichun Huang
- Web page: https://patentgrep.com/patent/US20120269819A1

## CPC

- C07K 16/249: {Interferons}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 5/16: for decreasing, blocking or antagonising the activity of the thyroid hormones
- A61P 5/40: Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/18: for HIV
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-γ) and methods for treating IFN-γ mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-γ. Methods of detecting the amount of IFN-γ in a sample using antibodies to IFN-γ are also provided.

## Claims

### Claim at position 1

1-30. (canceled)

### Claim 31

A method for treating a patient having systemic lupus erythematosus comprising administering to the patient a human anti-human IFNγ antibody, wherein the antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:34, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:35, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:36, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:38, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:41, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:43.

### Claim 32 (depends on 31)

The method of claim 31, wherein the antibody comprises the amino acid sequence of SEQ ID NO:6.

### Claim 33 (depends on 31)

The method of claim 31, wherein the patient has lupus nephritis.

### Claim 34 (depends on 33)

The method of claim 33, wherein the antibody comprises the amino acid sequence of SEQ ID NO:6.

### Claim 35 (depends on 32)

The method of claim 32, wherein the antibody comprises the amino acid sequence of SEQ ID NO:8.

### Claim 36 (depends on 34)

The method of claim 34, wherein the antibody comprises the amino acid sequence of SEQ ID NO:8.

### Claim 37 (depends on 31)

The method of claim 31, wherein the antibody comprises the amino acid sequence of SEQ ID NO:8.

### Claim 38 (depends on 33)

The method of claim 33, wherein the antibody comprises SEQ ID NO:8.

### Claim 39

A method for treating a patient having an inflammatory bowel disease comprising administering to the patient a human anti-human IFNγ antibody, wherein the antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:34, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:35, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:36, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:38, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:41, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:43.

### Claim 40 (depends on 39)

The method of claim 39, wherein the antibody comprises the amino acid sequence of SEQ ID NO:6.

### Claim 41 (depends on 39)

The method of claim 39, wherein the patient has Crohn's disease.

### Claim 42 (depends on 41)

The method of claim 41, wherein the antibody comprises the amino acid sequence of SEQ ID NO:6.

### Claim 43 (depends on 40)

The method of claim 40, wherein the antibody comprises the amino acid sequence of SEQ ID NO:8.

### Claim 44 (depends on 41)

The method of claim 41, wherein the antibody comprises the amino acid sequence of SEQ ID NO:8.

### Claim 45 (depends on 39)

The method of claim 39, wherein the antibody comprises the amino acid sequence of SEQ ID NO:8.

### Claim 46 (depends on 42)

The method of claim 42, wherein the antibody comprises SEQ ID NO:8.

### Claim 47

A method for treating a patient having psoriasis comprising administering to the patient a human anti-human IFNγ antibody, wherein the antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:34, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:35, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:36, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:38, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:41, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:43.

### Claim 48 (depends on 47)

The method of claim 47, wherein the antibody comprises the amino acid sequence of SEQ ID NO:6.

### Claim 49 (depends on 47)

The method of claim 47, wherein the antibody comprises the amino acid sequence of SEQ ID NO:8.

### Claim 50 (depends on 48)

The method of claim 48, wherein the antibody comprises the amino acid sequence of SEQ ID NO:8.
